Product Segment to Hold North America Point-Of-Care Molecular Testing For Infectious Diseases Market Share During 2023-2031

According to our new research study on " North America Point-Of-Care Molecular Testing For Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 1,098.37 million in 2023 to US$ 2,626.78 million by 2031. The North America point-of-care molecular testing for infectious diseases market is further anticipated to record a CAGR of 11.5% from 2022 to 2030. The surging prevalence of infectious diseases and preference for rapid diagnostic solutions are the key driving factors behind the market development. However, inadequate reimbursement scenario is hampering the market growth.

Infectious diseases adversely affect public health, causing morbidity, mortality, and economic burdens. The effective management, treatment, and prevention of these health conditions require accurate and timely diagnosis. Molecular diagnostics techniques, laboratory-based assays, and point-of-care tests are employed for the diagnosis of HIV, tuberculosis, and hepatitis C; human papillomavirus screening for cervical cancer; and the monitoring of health and treatment progress in patients. Healthcare providers turn to point-of-care testing to streamline diagnostic processes, reduce turnaround times, and enhance patient care. These tests also ease diagnoses during infectious disease outbreaks. According to data published by the CDC in 2022, Florida (US) suffered the onset of concurrent epidemics of hepatitis A, invasive meningococcal disease (IMD), and mpox (formerly known as monkeypox). Mpox cases were more strongly concentrated in South Florida and peaked in August. In contrast, the hepatitis A and IMD epidemics were centered in Central Florida and peaked from March to June. Nearly 2,845 cases of the mumps were reported in Florida as part of a worldwide outbreak. HIV infection was found in 52% of mpox patients compared to 21% of hepatitis A and 34% of IMD cases. These pathogens include hepatitis A, mpox, and meningococcal disease.

The reemergence of diseases such as tuberculosis, malaria, and hepatitis has necessitated the development of effective diagnostic tools to identify the causative agents and determine effective treatment regimens. According to the National Institutes of Health, 8,300 tuberculosis cases were reported in the US in 2022 compared to 7,874 cases reported in 2021. The incidence of tuberculosis rose a little from 2.4 per 100,000 people in 2021 to 2.5 per 100,000 persons in 2022. Thus, the surging prevalence of infectious disease propels the need for point-of-care testing over traditional techniques, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA). The COVID-19 pandemic further underlined the importance of rapid and accessible diagnostic testing for infectious diseases. The need for quick identification and containment of infectious pathogens propelled the demand for innovative point-of-care testing solutions in North America.

Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.

In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.

Abbott Laboratories, Agilent Technologies Inc, Becton Dickinson and Co, Bio-Rad Laboratories Inc, Cardinal Health Inc, Danaher Corp, Cue Health Inc, QuidelOrtho Corp, Thermo Fisher Scientific Inc, and F. Hoffmann-La Roche Ltd. are a few key companies profiled in the North America point-of-care molecular testing for infectious diseases market report.

Companies operating in the North America point-of-care molecular testing for infectious diseases market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the North America point-of-care molecular testing for infectious diseases market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall North America point-of-care molecular testing for infectious diseases market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below

• In February 2023, Thermo Fisher Scientific collaborated with Mylab to source RT-PCR kits for the detection of multidrug-resistant Mycobacterium tuberculosis (MDR MTB), hepatitis B and C viruses, and HIV; genetic analysis of HLA B27; and so on.
  
  
• In August 2023, QuidelOrtho Corporation-a global supplier of cutting-edge in-vitro diagnostic technologies intended for clinical labs, point-of-care settings, and transfusion medicine-won FDA approval for its De Novo request, enabling the business to commercialize its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA became the first fast antigen test to receive FDA market clearance for COVID-19 detection. The test can be utilized in point-of-care settings and is only meant to be used with a prescription.
  
  
• In March 2022, Quest Diagnostics launched two post-COVID-19 panels to provide information on health problems that may persist after prior COVID-19 virus infections. According to Quest, the Post-COVID-19 Basic Panel and Post-COVID-19 Expanded Test Panel offers customers a more thorough examination of their health and aid in getting them ready for conversations with their healthcare providers.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com